American Association for Cancer Research
Browse
crc-23-0304-s08.pptx (192.46 kB)

Figure S6 from Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor

Download (192.46 kB)
figure
posted on 2023-09-01, 14:20 authored by Shruti Lal, Neil E. Bhola, Bee-Chun Sun, Yuping Chen, Tom Huang, Vivian Morton, Kevin X. Chen, Shanghua Xia, Haoyu Zhang, Nehal S. Parikh, Qiuping Ye, O. Petter Veiby, David I. Bellovin, Yuhua Ji

ZL-2201 reduces DNA damage-induced MCM2 phosphorylation (Ser108).

Funding

ZaiLab (US) LLC

History

ARTICLE ABSTRACT

ZL-2201, a potent and selective DNA-PK inhibitor, can target tumor models in combination with DNA DSB-inducing agents such as radiation or doxorubicin, with potential to improve recurrent therapies in the clinic.

Usage metrics

    Cancer Research Communications

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC